非酒精性脂肪性肝病更名:从代谢功能障碍相关脂肪肝异质性到“同病异治”

Renaming non-alcoholic fatty liver disease:from metabolic dysfunction-associated fatty liver heterogeneity to"different treatment for the same disease"

关于非酒精性脂肪性肝病(NAFLD)更名为代谢功能障碍相关脂肪肝(MAFLD/MASLD)近两年来争议不断,期间大数据研究结果证明了NAFLD的时代局限性。重新审视命名法,可以正确认识NAFLD关键致病因素、了解其异质性及不同临床表型。目前NAFLD药物疗法临床应答率不高,通过分析其异质性,结合中医“同病异治”理论为临床诊断、研究、治疗NAFLD提供参考。

The renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty/steatotic liver disease (MAFLD/MAFLD) has been controversial for the last two years, during which the results of big data studies have proved the age-old limitations of NAFLD. Revisiting the nomenclature will allow for a proper understanding of the key causative factors of NAFLD, and an appreciation of its heterogeneity and different clinical phenotypes. The clinical response rate of NAFLD drug therapy is not high.By analyzing its heterogeneity and combining it with the theory of "different treatment for the same disease" in traditional Chinese medicine, we can provide references for clinical diagnosis, research, and treatment of NAFLD.